Table 1 Characteristics and molecular responses of CML-patients.
a)Patients 7 and 13 had similar responses at both 6 and 18 months.
Abbreviations: CP, chronic phase; BC, blast crisis; BrCa, breast cancer; C, complete; Ma, major; Mi, minor; I, Imatinib; N, Nilotinib; D, Dasatinib; R, Responsive; NR, not-responsive; NE, not-evaluated; Int, intermediate; BMA, bone marrow aplasia.